Lung Cancer Research at Providence Cancer Center
July 27, 2016
The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking.
Rachel E. Sanborn, M.D., co-director of the Providence Thoracic Oncology Program, specializes in thoracic oncology and clinical research. Her research focuses on studying new agents or combinations of treatments for lung cancer, mesothelioma and other thoracic tumors.
Following are two of the 14 lung cancer studies currently open to patients:
Title: A Phase I/II Study of Pembrolizumab (MK-3475) with Gemcitabine in Patients with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Description: This is a study for patients with previously treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug Pembrolizumab to standard treatment with gemcitabine. The study will also try to identify the best dose of Pembrolizumab to give in combination with gemcitabine.
Title: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive-Disease Stage Small-Cell Lung Cancer (SCLC) after Completion of Platinum based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
Description: The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression Free Survival compared with placebo in subjects with extensive stage disease small-cell lung cancer who have completed first line chemotherapy.
See more Providence studies